Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

David M Lowe, Li-An K Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai, Akosua A Agyeman, Anna Checkley, Nicola Longley, Hakim-Moulay Dehbi, Nick Freemantle, Judith Breuer, Joseph F Standing, FLARE Investigators
doi: https://doi.org/10.1101/2022.02.11.22270775

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted February 15, 2022.
Download PDF
Data/Code
Email
Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
David M Lowe, Li-An K Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai, Akosua A Agyeman, Anna Checkley, Nicola Longley, Hakim-Moulay Dehbi, Nick Freemantle, Judith Breuer, Joseph F Standing, FLARE Investigators
medRxiv 2022.02.11.22270775; doi: https://doi.org/10.1101/2022.02.11.22270775
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area